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Cisplatin is one of the most effective drugs available for the treat-
ment of a number of human solid tumours (in particular, testicular
and ovarian carcinoma). The clinical success of cisplatin has stim-
ulated intensive effort in the development of new platinum
compounds with improved pharmacological properties. In spite of
such effort, only carboplatin has emerged for clinical use as an
alternative analogue of cisplatin with comparable efficacy but an
improved toxicity profile. Unfortunately, development of drug
resistance is a major obstacle to successful treatment of human
tumours with cisplatin or carboplatin. The molecular basis of resis-
tance to cisplatin and related mononuclear analogues has not been
conclusively defined. Various mechanisms have been implicated,
including a number of cellular factors that affect the level of drug
reaching DNA and an enhanced DNA repair or increased tolerance
to DNA damage (Chu, 1994; Kelland, 1994; Fink et al, 1996; Crul
et al, 1997). Although the proposed mechanisms may contribute to
the development of a variable degree of cellular resistance, none of
them completely explains the intrinsic resistance of several
tumours or the pattern of cross-resistance among different DNA-
damaging agents.
Conventional platinum compounds (cisplatin and carboplatin)
are believed to mediate their cytotoxic effects through their inter-
action with DNA and formation of a variety of DNA adducts
(Eastman, 1987). Among the new platinum compounds with
potential activity against cisplatin-resistant cells are multinuclear
platinum complexes (Farrell, 1996). Such compounds, containing
two reactive platinum centers stably linked by a variable length
alkanediamine chain, were originally designed to form different
types of DNA adducts, such as ‘long-distance’ intra- and inter-
strand cross-links not available to conventional (i.e. mononuclear)
platinum complexes (Farrell, 1995a, 1995b). The structural
features and the multifunctional nature of such compounds are
expected to enhance the sequence specificity at DNA binding sites
(Farrell, 1995b). By structure–activity relationship studies, we
selected for further development a trinuclear platinum complex
(BBR 3464) characterized by a promising profile of cytotoxic
activity and efficacy against cisplatin-resistant cell lines (Farrell,
1997). The chemical structure and conformation of BBR 3464 are
shown in Figure 1.
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Summary Multinuclear platinum compounds were rationally designed to bind to DNA in a different manner from that of cisplatin and its
mononuclear analogues. A triplatinum compound of the series (BBR 3464) was selected for preclinical development, since, in spite of its
charged nature, it was very potent as cytotoxic agent and effective against cisplatin-resistant tumour cells. Anti-tumour efficacy studies were
performed in a panel of human tumour xenografts refractory or poorly responsive to cisplatin. The novel platinum compound exhibited efficacy
in all tested tumours and an impressive efficacy (including complete tumour regressions) was displayed in two lung carcinoma models, CaLu-
3 and POCS. Surprisingly, BBR 3464 showed a superior activity against p53-mutant tumours as compared to those carrying the wild-type
gene. The involvement of p53 in tumour response was investigated in an osteosarcoma cell line, SAOS, which is null for p53 and is highly
sensitive to BBR 3464, and in the same cells following introduction of the wild-type p53 gene. Thus the pattern of cellular response was
investigated in a panel of human tumour cells with a different p53 gene status. The results showed that the transfer of functional p53 resulted
in a marked (tenfold) reduction of cellular chemosensitivity to the multinuclear platinum complex but in a moderate sensitization to cisplatin. In
addition, in contrast to cisplatin, the triplatinum complex was very effective as an inducer of apoptosis in a lung carcinoma cell line carrying
mutant p53. The peculiar pattern of anti-tumour activity of the triplatinum complex and its ability to induce p53-independent cell death may
have relevant pharmacological implications, since p53, a critical protein involved in DNA repair and induction of apoptosis by conventional
DNA-damaging agents, is defective in several human tumours. We suggest that the peculiar DNA binding properties of the triplatinum
complex may contribute to the striking profile of anti-tumour efficacy. Taken together, the available information supports that anti-tumour
activity of the novel compound is mediated by a mechanism different from that of conventional platinum complexes, and compounds of this
series could represent a new class of promising anti-tumour agents.
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We explored the anti-tumour effects of BBR 3464 in a large
number of cisplatin-resistant solid human tumours, with the aim to
define the profile of preclinical anti-tumour efficacy. In this study,
we documented an improved efficacy of the novel complex in
all tested models and a marked efficacy in carcinoma models with
mutant p53. A role of wild-type p53 in determining resistance
to the novel platinum compound was also supported by cellular
pharmacology studies.
MATERIALS AND METHODS
Drugs
BBR 3464 was prepared as NO3 salt (Figure 1A) (Farrell, 1997).
The structure identity was confirmed by two independent synthetic
methods and further supported by X-ray crystallography data
(Farrell et al, manuscript in preparation) (Figure 1B). Cisplatin
was a product of Bristol-Myers Squibb. All drugs were dissolved
in saline immediately before use.
In vivo studies
Human tumour lines were derived from cell cultures (CaLu-3,
POVD/DDP, A2780/CP, IGROV/DDP, DU145, H460, A549,
SKOV-3) or directly from surgical specimens (LX-1, POCS).
They were maintained in athymic nude mice by serial subcuta-
neous (s.c.) passages of tumour fragments. Athymic Swiss nude
mice, 10–12 weeks old, were used throughout the study (Charles
River Laboratories, Calco, Italy). Mice were maintained in
laminar flow-rooms, according to the guidelines of the Istituto
Nazionale per lo Studio e la Cura dei Tumori of Milan.
Experimental protocols were approved by the Ethics Committee
for Animal Experimentation according to the UKCCCR guidelines
(Workman et al, 1988).
For chemotherapy experiments, mice were s.c. grafted with
tumour fragments in both flanks. Each experimental group
consisted of 8–10 tumours. Tumour growth was followed and
tumour weight (TW) was calculated measuring tumour diameters
with a vernier caliper and using the formula: TW (mg) = tumour
volume (mm3) = d2 ´ D/2, where d and D represent the shortest
and the longest diameter respectively.
When tumours weighed around 50–100 mg, mice were treated
intravenously with cisplatin or BBR 3464 (both dissolved in
saline). Treatments were repeated weekly for a total of 3 times
(q7d´3). Drug efficacy was assessed using two conventional para-
meters:
1. relative tumour weight inhibition (RTWI%) in treated (T)
versus control (C) mice according to the formula:
1002[TWT/TWc´100]
2. specific growth delay (SGD) calculated as (T2C)/C where
T is days for treated tumours and C days for control tumours
taken to double (SGD 1–2) or quadruplicate (SGD 1–4) their
initial weight.
A tumour was considered responsive when the treatment
achieved an SGD ³ 1.5. Mean values were used for all calcula-
tions. Mice were weighed weekly during the experimental time
frame, and results are presented for drug doses causing a body
weight loss ≤ 15%.
Statistical comparison of TW in cisplatin- vs BBR 3464-treated
tumours was assessed by Student’s t-test (two-tailed).
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Figure 1 Chemical structure (A) and conformation of BBR 3464 (B)1914 G Pratesi et al
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Cell lines and cytotoxicity studies
Tumour cell lines were maintained in RPMI-1640 plus 10% fetal
calf serum. Cytotoxicity was assessed by growth-inhibition assay.
Briefly, 24 h after seeding, cells were exposed to the drug for 1 h
and then incubated in drug-free medium for 72 h and counted with
a ZBI Coulter counter (Coulter Electronics Ltd, Luton, UK). In
long-term exposures, cells were maintained in the presence of drug
for 72 h. The 50% inhibitory concentration (IC50) was calculated
from dose–response curves.
Apoptosis and cell cycle analysis
The extent of apoptosis was assessed by fluorescence microscopy
as already described (Perego et al, 1996; Caserini et al, 1997).
Briefly, at the end of exposure to drug, cells were fixed in cold
Table 1 p53 status in human tumour models
p53 statusa
Tumour Tumour Mutation Nucleotide Amino acids
model type Resistance Exon Codon change substitution
p53 wild-type
H460 non-SCLC Intrinsic
A549 non-SCLC Intrinsic
A2780/CP Ovarian Acquired
SKOV-3b Ovarian Intrinsic
p53 mutant
CaLu-3 non-SCLC Intrinsic 7 237 ATG®ATT (L) Met®Ile
LX-1 non-SCLC Intrinsic 9 309 CCC®TCC Pro®Ser
POCS SCLC Intrinsic 7 242 TGC®TTC (L) Cys®Phe
POVD/DDP SCLC Acquired 5 171 GAG®TAG (LH) Glu®Stop
IGROV/DDP Ovarian Acquired 8 270 TTT®TTA Phe®Leu
282 CGG®TGG (LSH) Arg®Trp
DU145 Prostatic Intrinsic 6 223 CCT®CTT Pro®Leu
8 274 GTT®TTT (LSH) Val®Phe
aExons 5–9 were analysed. In parenthesis: structural/functional domain of p53 according to Volgestein and Kinzler (1994). bNo endogenous expression of p53.
SCLC, small-cell lung carcinoma.
Table 2 Comparison of efficacy of cisplatin and BBR 3464 on human carcinoma xenografts (s.c.). Treatment i.v., q7dx3
Tumour Growth ratea Drug Optimal doseb TWIc SGDd
model (mg kg–1) (%)
1–2 1–4 1–2 1–4
H460 2.5 7.5 Cisplatin 6 42 0.4 0.6
BBR 3464 0.4 64** 0.6 1.6
A549 7.5 19.5 Cisplatin 6 18 0 0.5
BBR3464 0.3 45* 0 1.6
0.4 64* 2.3 3.1
A2780/CP 2.5 5 Cisplatin 4 48 0.2 0.2
BBR 3464 0.3 63 0.2 2.0
SKOV-3 5.5 13 Cisplatin 6 21 0.4 0.3
BBR 3464 0.4 60* 1.9 2.4
CaLu-3 5.5 11 Cisplatin 6 60 1.2 0.9
BBR 3464 0.3 92***(5/11) ND ND
LX-1 3.7 7.5 Cisplatin 4 39 0.4 0.5
BBR 3464 0.3 77* 0.8 2.2
POCS 12 21 Cisplatin 6 56 0.1 0.75
BBR 3464 0.4 92**(4/6) ND ND
POVD/DDP 3.5 7 Cisplatin 6 70 0.7 1.0
BBR 3464 0.3 85* 1.6 3.3
0.4 93** 8.1 4.9
IGROV/DDP 4 8.5 Cisplatin 6 68 0.75 1.5
BBR 3464 0.3 80 3.25 3.7
DU145 3 8 Cisplatin 6 30 0.2 0.4
BBR 3464 0.4 63 2.0 1.4
aDays required for control tumours to double or quadruplicate their initial weight. bMaximum tolerated dose with the indicated schedule.
cInhibition of relative tumour weight in treated versus control mice. *P < 0.05; **P < 0.01; ***P < < 0.01 (by Student’s t-test) versus
cisplatin-treated tumours in the same experiment. In parenthesis, partial or complete tumour regressions at the end of experiment.
dSpecific growth delay in treated compared to control tumours to reach twice (1–2) and four times (1–4) their initial weight. Calculations
were done as specified in the Methods. ND, not determined because of partial or complete regression of treated tumours.Multinuclear platinum complex and p53-mutant tumours 1915
British Journal of Cancer (1999) 80(12), 1912–1919 © 1999 Cancer Research Campaign
70% ethanol, stained with propidium iodide (PI) solution (30 mg
ml–1 PI and 66 U ml–1 RNAase in phosphate-buffered saline) and
stored in the dark for 30 min. At least 100 cells in two different
smears for each sample were examined for morphological
changes. The percentage of apoptotic cells was referred to the total
cell number. To investigate cell cycle distribution the fluorescence
intensity of PI-stained cells was determined by FACScan flow
cytometer (Becton Dickinson, Mountain View, CA, USA).
Transfection of p53-deficient SAOS cells with a wild-
type p53 expression vector
SAOS cells were seeded in 6-well plates and transfected when
they reached 70% confluency. Each well was incubated for 4 h
with serum-free medium containing 30 ml of lipofectin (Gibco
BRL, Life Technologies Inc., Gaithersburg, MD, USA) and 3 mg
of DNA consisting of the wild-type p53 expression plasmid
pCMV-SN3 or a parental of the former as control. The pCMV-SN3
plasmid was kindly supplied by Dr Bert Vogelstein (Johns
Hopkins Oncology Center, Baltimore, MD, USA). Medium was
replaced with serum containing medium and 48 h later selection
was started by adding 400 mg ml–1 geneticin. Geneticin-resistant
cells were maintained in selective medium.
Western blot analysis
Western blot analysis of cell lysates was performed as previously
described (Perego et al, 1996). Briefly, samples were fractionated
by sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) and blotted on nitrocellulose sheets. Blots were then
preblocked for 1 h at room temperature in phosphate-buffered
saline containing 5% (w/v) dried non-fat milk. Filters were incu-
bated overnight at 4°C with an antibody to p53 (DO-7, Dako,
Glostrup, Denmark) to p21WAF1 (Neomarkers, Fremont, CA, USA)
or to MDM2 (Oncogene Research, Cambridge, MA, USA). A
rabbit antiserum to recombinant human HAP1 or to actin (Sigma,
St Louis, MO, USA) was used as control for loading since these
proteins are equally expressed in the studied cell lines. Antibody
binding to filters was detected by the enhanced chemilumines-
cence luciferase method (Amersham, Little Chalfont, UK).
SSCP and sequencing analysis of the p53 gene
Single-strand conformation polymorphism (SSCP) and
sequencing analysis for detection of p53 gene mutations in the
most affected exons 5–9 were performed as previously described
(Perego et al, 1996). Briefly, SSCP bands recovered from gels
were used as templates in direct sequencing reactions using the
Amplitaq Cycle Sequencing kit (Perkin-Elmer, Branchburg, NJ,
USA). In Tables 1 and 3, p53 gene is referred as wild-type if muta-
tions in exons 5–9 were not detected.
RESULTS
Anti-tumour efficacy studies
The biological and molecular profiles of the human tumour
models used in this study are summarized in Table 1. The panel
included ten carcinoma xenografts of different tumour types,
including six lung, three ovarian and one prostatic carcinoma. The
tumours were chosen, because, in our experience, they were rela-
tively resistant to cisplatin. The resistant status was more evident
for the seven tumours with intrinsic resistance. In all our tumour
models, we determined the p53 status. The SSCP and sequence
analysis revealed p53 mutations in 6/10 tumours. The pattern of
tumour response to cisplatin or to the multinuclear complex
BBR 3464 is shown in Table 2, which summarizes the effects of
drug treatment using optimal doses for each agent (i.e. maximum
Table 3 Cytotoxic effects of cisplatin and BBR 3464 in human tumour cell lines with different p53 status or expression
IC50 (mg/ml)a
Cisplatin BBR 3464
Cell lines
(tumour type) p53 status 1 h 72 h 1 h 72 h
A2780 Wild-type 1.2 ± 0.03 0.06 ± 0.01 0.032 ± 0.001 0.012 ± 0.004
(ovarian carcinoma)
A2780/CP Wild-type 35 ± 2.8 (29) 0.73 ± 0.2 (12) 2.0 ± 0.2 (62) 0.29 ± 0.2 (24)
(ovarian carcinoma)
IGROV-1 Wild-type 4.3 ± 1.3 8.0 ± 2.8
(ovarian carcinoma)
U2-OS Wild-type 2.4 ± 0.1 1.7 ± 0.01
(osteosarcoma)
SW626 Mutant (codon 273) 6.3 ± 3.0 0.08 ± 0.03
(ovarian carcinoma)
SAOS Null 3.0 ± 0.2 0.1 ± 0.01
(osteosarcoma)
POGB Mutant (codon 282) 0.25 ± 0.07 0.009 ± 0.006
(SCLC)
A431 Mutant (codon 273) 10.4 ± 3 3.1 ± 1.8
(cervical carcinoma)
aCytotoxicity following the indicated exposure to the drug was determined by growth inhibition test as described in the Methods. IC50 values (±SD) were deduced
from dose–response curves. In parenthesis: resistance index.1916 G Pratesi et al
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tolerated doses causing ≤ 15% body weight loss and ≤ 10% of
lethality). Cisplatin treatment achieved less than 60% TWI in
seven of the ten tumour systems. Although in three other tumours
drug effects were pharmacologically appreciable (TWI between 60
and 70%), all tumours of this panel should be considered resistant
or poorly responsive to cisplatin, as evidenced by marginal SGD
values (≤ 1.5). In contrast, BBR 3464 exhibited a remarkable anti-
tumour activity, resulting in TWI > 60% and SGD > 1.5, in all
tested tumour models. In most tumour systems, the inhibition
lasted for a long time, as documented by SGD values (Table 2) and
shown in representative growth curves (Figure 2). A striking
finding of this study was hypersensitivity of most p53-mutant
tumours (TWI > 75% in five tumours) compared to tumours with
the wild-type gene. In the tumours carrying wild-type p53,
TWI achieved by BBR 3464 did not exceed 75%. Among the
p53-mutant tumours, impressive was the activity against three
lung carcinomas, i.e. CaLu-3 and POCS, in which partial or
complete regressions were produced in most treated tumours, and
POVD/DDP, in which the highest SGD value was achieved. In
spite of the presence of wild-type p53 gene, SKOV-3 should be
regarded as p53-deficient model, since no protein expression could
be detected. Again, this tumour model was markedly more respon-
sive to BBR 3464 than to cisplatin, which was almost ineffective.
The activity achieved by BBR 3464 in this tumour is relevant,
considering its intrinsic resistance to several conventional agents.
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Figure 2 In vivo response of human tumour xenografts following treatment with cisplatin or BBR 3464. Abscissa: days after first drug treatment. Ordinate:
mean relative tumour weights (TW), calculated by dividing the mean TW at each time by the mean TW at day 1 (1st day of treatment) ´ 100. Drug treatments
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Figure 4 Western blot analysis of p53, p21 and MDM2 in p53-deficient and
wild-type p53-transfected SAOS cells. 1, p53-deficient cells; 2, empty vector
transfected cells; 3, wild-type p53-transfected cells. Control loading is shown
by actin
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Figure 5 Effect of transfection of p53-deficient SAOS cells with a wild-type
p53 expression vector on cytotoxicity of cisplatin or BBR 3464. Cells were
exposed to the drug for 1 h and cytotoxic effect was determined by the
growth inhibition test as described in the Methods. (n) SAOS cells treated
with cisplatin; (•) BBR 3464-treated SAOS cells; wt-p53 expressing cells
treated with cisplatin (n n) or BBR 3464 (l l); empty vector-transfected cells
treated with cisplatin (u u) or BBR 3464 (D)Multinuclear platinum complex and p53-mutant tumours 1917
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Pattern of chemosensitivity of human tumour cells
Based on observations concerning anti-tumour activity, a compar-
ative study of cellular response to cisplatin and BBR 3464 was
performed in a panel of eight human tumour cell lines of various
tumour types. The panel included four cell lines containing wild-
type p53 and four p53-deficient cell lines. The pattern of cellular
response (Table 3) was consistent with in vivo tumour response,
since in general p53-mutant or deficient cells were more sensitive
to BBR 3464 than cell lines with wild-type p53. In contrast, p53-
mutant cells showed comparable or somewhat reduced sensitivity
to cisplatin compared to wild-type p53-containing cells. Among
tumour cells with wild-type p53, the cisplatin-resistant subline
(A2780/CP) exhibited a marked cross-resistance to BBR 3464.
The observation that an increased expression of p53 protein was
present in the resistant subline (Figure 3) is consistent with a role
of p53 in cellular response to BBR 3464. The functionality of p53
in A2780/CP is questionable, since no elevation of p21WAF-1 protein
could be detected after exposure to cisplatin (Perego et al, 1997).
However, based on the multifunctional nature of p53, an involve-
ment of p53 could not be ruled out, as suggested by an increased
cell ability to repair DNA damage (Caserini et al, 1997).
No precise correlation between p53 status and drug sensitivity
can be expected from our panel of cell lines, since multiple factors
affecting chemosensitivity may be expressed in a variable manner
in cells of different tumour types. Thus, to overcome the difficulty
in separating the effects of multiple alterations expected in non-
isogenic systems, the role of p53 in response to platinum
compounds was investigated in a comparative study of osteosar-
coma cells, SAOS (defective in p53 function), following transfec-
tion with the wild-type gene. A polyclonal population expressing
p53, and two p53-regulated genes (p21WAF1 and MDM2) was used
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Figure 7 Apoptosis induction by cisplatin or BBR 3464. (A) A2780/CP cells were exposed to the drug for 1 h and the extent of apoptotic cells was determined
at the indicated times; (B) POGB cells were exposed to cisplatin (•) or BBR 3464 (s) for 72 h. The percentage of apoptotic cells in the whole population was
determined by fluorescence microscopic observation of propidium iodide-stained cells. At least 100 cells from two different smears were examined for nuclear
morphological changes
Figure 6 Cell cycle distribution of p53-deficient (n) and wild-type p53-transfected SAOS cells (n n) exposed to cisplatin or BBR 3464. Seventy-two hours after a
1 h exposure to the drug (3 mg ml–1), cells were processed for FACScan analysis. The percentage of cells in the different phases of cell cycle was obtained by
computer analysis of DNA hystograms1918 G Pratesi et al
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(Figure 4). Introduction of a functional p53 gene significantly
reduced (around tenfold) sensitivity of SAOS cells to BBR 3464
(Figure 5). An opposite effect was found on cisplatin sensitivity,
since transfection resulted in an appreciable sensitization. The cell
cycle analysis indicated that cisplatin induced a comparable
perturbation of cell cycle in the isogenic systems, as expected for a
DNA damaging agent (i.e. accumulation of cells in G2 phase).
This effect was also evident in BBR 3464-treated cells but more
marked in p53-tranfected cells, thus suggesting that the role of p53
in G2-checkpoint may be more relevant for DNA lesions induced
by the multinuclear platinum complex (Figure 6).
Since cellular sensitivity to platinum compounds has been
related to their ability to induce apoptosis, drug ability to trigger an
apoptotic response was explored in two cell lines of our panel,
including the resistant ovarian carcinoma A2780/CP, with wild-
type p53 gene sequence and the small-cell lung carcinoma cell line
POGB, with mutant gene (Supino et al, 1996). In both cell
systems, the increased cytotoxic potency of BBR 3464, compared
to cisplatin, reflected a marked susceptibility to apoptosis induc-
tion (Figure 7).
DISCUSSION
This study showed that the cationic trinuclear platinum complex,
BBR 3464, is characterized by a marked increase (up to 50-fold) in
cytotoxic potency as compared to cisplatin and an outstanding effi-
cacy in the treatment of cisplatin-resistant tumours. The increased
cytotoxic and anti-tumour potency is somewhat surprising on the
basis of its charged nature. The high level of anti-tumour activity
in all cisplatin-resistant tumours suggests the drug ability to over-
come multiple mechanisms of cisplatin resistance. Among the
tumours included in our panel, the BBR 3464 complex exhibited
an impressive level of anti-tumour activity against tumours
containing a mutant p53. The pattern of tumour response was
surprising, since loss of wild-type p53 function could lead to
intrinsic resistance as a consequence of a reduced susceptibility to
apoptosis following DNA damage. Indeed, apoptosis is recognized
as a major mode of cell death induced by cisplatin as well as many
DNA-damaging anti-tumour agents (Perego et al, 1996; Zunino et
al, 1997).
Since in all p53-mutant tumours no wild-type sequence could be
detected at the site of mutation, a consistent loss of function of
wild-type p53 was expected. In particular, the mutation found in
CaLu-3, resulting in substitution of Met with Ile at the start of loop
3 of p53 (residue 237) has been shown to give a completely mutant
phenotype in terms of conformational analysis (Rolley et al, 1995).
The mutation found in LX-1 (codon 309), localized outside the
central evolutionary conserved sequence-specific DNA binding
domain, involves a phosphorylation site required alone or with
Ser313 for p53 DNA binding activity (Hecker et al, 1996). POCS
exhibits a mutation (codon 242) which behaves as dominant nega-
tive, as documented by assays carried out in yeast (Brachmann et
al, 1996). Based on the crystal structure of the central portion of
human p53 complexed with DNA (Vogelstein et al, 1994), such a
mutation is conceivable to destabilize p53 altering its function-
ality, since Cys242 participates in coordinating a Zn atom to the
protein loops. Regarding the POVD/DDP tumour, the codon 171
mutation is expected to lead to a truncated protein lacking most of
the regions required for p53 oligomerization (319–360) and for
DNA damage recognition (311–393). Loss of p53 function has
been observed in the cellular system from which IGROV/DDP
xenograft was originated. These cells, carrying p53 mutation at
codons 270 and 282, lack G1 control after radiation and p21 induc-
tion after DNA damage (Perego et al, 1996). At least one of the
two mutations found in DU145 (codon 223) has been previously
shown to result in loss of p53 functionality, as indicated by loss
of G1 arrest, of inducibility of p21WAF1 and GADD45 and
MDM2 mRNA after radiation (O’Connor et al, 1997). In the
p53-mutant tumours of our panel, resistance to cisplatin could be
predicted on the basis of recent advances in knowledge of the
molecular pathways of apoptosis activated by DNA-damaging
agents (Lowe et al, 1994; Hickman, 1996; Zunino et al, 1997).
Recently, a correlation has been found between mis-sense muta-
tions and clinical resistance of advanced ovarian carcinoma treated
with cisplatin-based therapy (Righetti et al, 1996).
In addition to a role of p53 in modulating apoptosis, p53-medi-
ated cellular responses include cell growth arrest, which is
required to allow DNA repair prior to genome replication (Kastan
et al, 1995; Zunino et al, 1997). The p53 protein itself has been
implicated in the recognition and repair of damaged DNA (Wang
et al, 1995; Harris, 1996). Based on p53 functions, a plausible
explanation for the hypersensitivity of human tumours with mutant
p53 to BBR 3464 is that apoptosis induced by the drug is not medi-
ated by p53, which in the wild-type form could enhance the cell’s
efficiency to repair DNA damage. If this interpretation is correct,
overexpression of wild-type p53 might reduce sensitivity to BBR
3464. Similarly, introduction of wild-type p53 in cells lacking p53
function resulted in a significant resistance to BBR 3464. It is thus
conceivable that, in tumour cells containing a functional p53,
repair of BBR 3464-induced DNA lesions prevails over apoptosis
triggering.
The efficacy of BBR 3464 in tumours with mutant p53 suggests
that a p53-independent response can be activated by the DNA
lesions induced by this agent. Indeed, a human small-cell lung
carcinoma cell line (POGB), characterized by loss of p53 function
as a consequence of mutation and relatively resistant to cisplatin
(Supino et al, 1996), was very sensitive to BBR 3464, and cytotox-
icity reflected a marked susceptibility to apoptosis induction by
BBR 3464. An alternative explanation for BBR 3464 efficacy
against p53-mutant tumour cells could be a persistent cytostatic
effect, likely related to the cell’s inability to recognize and repair
specific DNA lesions induced by BBR 3464 and resulting in
delayed apoptosis or in a different cell death pathway. Such an
interpretation is consistent with the persistent tumour growth inhi-
bition observed after in vivo treatment.
The impetus for development of new platinum complexes, with
genuinely new structures compared to cisplatin, comes from the
consideration that clinical trials of conventional cisplatin
analogues have, in general, not produced drugs with an enhanced
spectrum of anti-tumour activity. Sequence specificity, conforma-
tional changes and interactions with DNA-processing proteins of
direct cisplatin analogues are similar to those of the parent drug.
Thus, the biological effects are expected to be the same, and
differences in anti-tumour activity and toxicity may be dictated by
differences in pharmacokinetics or reactivity rather than enhanced
inhibition of target (DNA) functions. As a corollary, platinum
compounds structurally dissimilar to cisplatin may, by virtue of
formation of different types of platinum-DNA adducts, exhibit a
spectrum of clinical activity complementary to the parent drug,
and it is this hypothesis that has driven our drug design efforts
(Farrell, 1993). The bifunctional DNA binding of BBR 3464 is
similar to that extensively outlined for dinuclear platinumMultinuclear platinum complex and p53-mutant tumours 1919
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complexes (Farrell, 1996). The central hydrogen-bonding core of
BBR 3464 enhances kinetics of binding, but conformational
changes of DNA are similar to those previously described. They
include a high proportion of interstrand cross-links, where the
platinated bases on each strand are separated by up to as many as
4 base pairs, and the irreversible induction of the left-handed
Z-DNA conformation (Johnson et al, 1992; Wu et al, 1996). These
DNA adducts are unique to the class of di- and trinuclear platinum
complexes and are discrete both from cisplatin and the alkylating
agents such as melphalan and chloroambucil. The lack of cross-
resistance and the increased cytotoxic potency of the novel multi-
nuclear platinum complex support a different mechanism of DNA
interaction (Perego et al, 1999).
In conclusion, the identification of a new class of DNA-
damaging agents exhibiting high activity in p53-mutant tumours
was an unpredictable outcome from our programme of systematic
synthesis. Further studies could be of fundamental importance in
designing even newer agents capable of triggering p53-indepen-
dent cell death. Indeed, the discovery of agents with preferential
toxicity against p53 mutant tumour cells should be considered an
important goal in the development of new effective anti-tumour
agents (O’Connor et al, 1997), because inactivation of p53 func-
tion, as a consequence of mutation or deletion of the gene, occurs
in many human tumours, including tumour types relatively
responsive to cisplatin (e.g. lung and ovarian carcinoma).
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